PubMed Health⌕ Search

Biomedical subjects

I S Khomenko

Publications and source records attributed to I S Khomenko.

13 recordsLinked to original sources
PubMed1995

[Cytokines in tuberculosis].

The paper presents the data available in the literature and the authors' own findings concerning the production of cytokines, such as interleukins 1, 2, 4, 6, and 8, interferons and tumor necrosis factor, in patients with different stages of tuberculosis. A relationship between the production rate of some cytokines and the stage of the disease, the extent of the process, chemotherapeutical efficiency and other clinically important factors is discussed. The prospects of further investigations in this area are dealt with.

Antitubercular Agents↗
PubMed1991

[A new method of the evaluation of lymphocytes and monocytes during immune response in patients with tuberculosis and sarcoidosis].

Examination which included 21 patients with tuberculosis, 6 with sarcoidosis and 9 healthy volunteers was aimed at determining the amount and intensity of surface fluorescence of CD+3, CD+4, CD+8 lymphocytes and CD14+, KIM+I monocytes. The findings demonstrate that determination of the fluorescence intensity of lymphocytes and monocytes provides a more exact characterization of the morphofunctional state of cells involved in the immune response. It is shown in particular that tuberculosis and sarcoidosis patients exhibit a varying density of the expressed antigenic markers of lymphocytes, which increases only in sarcoidosis, except a suppressor subpopulation (cytotoxic lymphocytes). Patients with tuberculosis had decreased density of CD9+, CD14+ and KIMI markers on the particular subpopulations.

Adult↗
PubMed1991

[Treatment of immunodeficient conditions caused by viral infection with the Soviet immunomodulator kemantan in patients with pulmonary tuberculosis].

Observation of 219 patients with pulmonary tuberculosis was made to study the effect of acute respiratory viral infection (ARVI) on the course of the disease. The affected were divided into 2 groups: 136 subjects who had ARVI and 83 persons who did not have it during their stay at a hospital. Patients with infiltrative pulmonary tuberculosis, and young and middle-aged men were prevalent in both groups. It was found that ARVI promoted the aggravation of a specific process in the lungs in 19.1 per cent of the patients. Keeping in mind a large proportion of aggravations and low immunologic indices as a consequence of ARVI, 14 patients were put on kemantan. Study of the immune status of the patients who had ARVI and received kemantan demonstrated a significant increase in the formation of blasts and the concentration of T cells whose functional activity tended to rise. At the same time the above-mentioned indices remained intact or tended to drop in patients receiving no kemantan. The Soviet immunomodulator kemantan is recommended for a combined treatment of the pulmonary tuberculosis patients who had intercurrent viral infection to stimulate cellular immune defences and prevent an aggravation of the specific process.

Adamantane↗
PubMed1991

[Natural killer cells in patients with pulmonary tuberculosis].

In the existent literature the number of works devoted to the subpopulation of natural killer cells (NK) is not significant. The purpose of the present study was to determine the NK content in the blood of pulmonary tuberculosis patients; to establish correlation of the level of their content with the content of the previously studied T-lymphocyte subpopulations; to determine the intensity of the fluorescence of NK, CD3+, CD4+, CD8+ lymphocytes. The data were obtained on the significant increase in the NK mean level in tuberculosis patients (20.37 +/- 1.74) as compared with that in healthy subjects (12.77 +/- 2.56). The NK fluorescence intensity (56.33 +/- 2.28) conditioned by the Fc-receptor expression intensity is significantly lower than the analogous index in healthy volunteers (82.4 +/- 7.69). The NK level in the blood of tuberculosis patients correlates with the content of CD3+, CD8+ lymphocytes as well as with the CD4+/CD8+ index.

Antibodies, Monoclonal↗
PubMed1990

[Effectiveness of antitubercular chemotherapy combined with corticosteroids and immunomodulators].

One hundred forty eight patients with common forms of pulmonary tuberculosis in an outbreak phase and the presence of secondary immunodeficiency were observed. Caverns were found in 80.4% and bacterial excretion, in 87.16% of the cases. Group 1 (71 persons) received chemotherapeutic drugs only; group 2 (21 persons), chemotherapeutic drugs and T-activin; group 3 (33 persons), chemotherapeutic drugs and corticosteroids; and group 4 (23 persons), chemotherapeutic drugs, corticosteroids and T-activin. The bacterial excretion in all the groups was found to be the same. The regression of infiltrative changes in the lungs by the 6-th month of treatment was more significantly registered in the groups of patients on a regimen containing chemotherapeutic drugs, corticosteroids and T-activin. Cavern closure rate appeared to be the lowest in subjects receiving chemotherapeutic drugs and corticosteroids; the addition of T-activin increases the cavern closure index. The combination of chemotherapeutic drugs, corticosteroids and T-activin promotes the normalization of the cellular immunity and increases the efficacy of pulmonary tuberculosis treatment.

Adjuvants, Immunologic↗
PubMed1990

[Use of T-activin in patients with sarcoidosis].

In sarcoidosis patients, comparison of the outcomes of treatment with corticosteroids alone (n = 142) or in combination with T-activin (n = 20) showed a marked positive effect of T-activin on the improvement of the patients' immunologic status and pronounced regression of changes in the lungs and intrathoracic lymph nodes. Indications for T-activin administration were defined and its treatment regimen was suggested.

Adjuvants, Immunologic↗
PubMed1989

[The blood count of regulatory T-lymphocyte subpopulations in patients with pulmonary tuberculosis].

Important aspects are discussed of clinical evaluation of regulatory subpopulations of T-lymphocytes (T-helpers and T-suppressors) in the blood of patients with pulmonary tuberculosis. Imbalance of these subpopulations in the patients with normal values of E-REG BTR with PHA allows to establish immunity disorders in supplementary group of patients. Subpopulation imbalance is an unfavourable prognostic sign and one of indications to immunomodulating therapy.

Female↗
PubMed1989

[Efficacy of treating patients with disseminated forms of destructive pulmonary tuberculosis using chemical preparations and T-activin].

The use of T-activin in combination with chemical drugs allowed to markedly increase efficacy of the treatment. As a result of the treatment significant improvement was found in 17 (41.5 per cent) out of 41 patients with marked disorders in cellular immunity and severe tuberculosis. At the same time in the patients treated with the chemotherapeutics alone the improvement was stated only in 18.5 per cent of the patients. T-Activin improved the indices of cellular immunity and eliminated imbalance in regulatory subpopulations of T-helper and T-suppressor cells.

Adjuvants, Immunologic↗